Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 7/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134138 | 0.89 | RORC (0.40) | POLBALOX15TSHRCASP1CNR2 | |
| SCHEMBL6134607 | 0.89 | POLB (0.39) | POLBTSHRCNR2KDM4EALDH1A1 | |
| SCHEMBL6133813 | 0.88 | ALOX15 (0.46) | POLBALOX15TSHRCASP1KDM4E | |
| SCHEMBL6133317 | 0.87 | MAPT (0.46) | POLBAVPR1BCNR2KDM4EALDH1A1 | |
| SCHEMBL6133413 | 0.86 | PDE4A (0.46) | POLBKDM4EALDH1A1 | |
| SCHEMBL6134702 | 0.84 | ADORA2A (0.49) | POLBALOX15TSHRKDM4EALDH1A1 | |
| SCHEMBL6133040 | 0.82 | GABRA5 (0.40) | ALOX15TSHRCASP1KDM4EALDH1A1 | |
| SCHEMBL6134397 | 0.82 | TGFBR1 (0.53) | POLBALOX15TSHRKDM4EALDH1A1 | |
| SCHEMBL6134156 | 0.80 | TSHR (0.42) | POLBALOX15TSHRCASP1KDM4E | |
| SCHEMBL6134642 | 0.79 | TP53 (0.41) | POLBALOX15TSHRCASP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | POLB 3447/4885ALOX15 1491/4885TSHR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.